Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M71,524Revenue $M6,494Net Margin (%)20.8Z-Score5.8
Enterprise Value $M71,945EPS $1.7Operating Margin %27.1F-Score7
P/E(ttm))51.4Cash Flow Per Share $4.4Pre-tax Margin (%)24.2Higher ROA y-yN
Price/Book14.710-y EBITDA Growth Rate %0Quick Ratio5.2Cash flow > EarningsY
Price/Sales10.85-y EBITDA Growth Rate %22.2Current Ratio5.4Lower Leverage y-yN
Price/Cash Flow17.9y-y EBITDA Growth Rate %2.8ROA % (ttm)9.4Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)30.2Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M801ROI % (ttm)17.8Gross Margin Increase y-yY

Gurus Latest Trades with CELG

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CELGGeorge Soros 2014-06-30 Buy 0.45%$68.45 - $86.8
($75.89)
$ 89.0917%New holding, 688000 sh.688,000
CELGJoel Greenblatt 2014-06-30 Buy 0.07%$68.45 - $86.8
($75.89)
$ 89.0917%New holding, 63980 sh.63,980
CELGRonald Muhlenkamp 2014-06-30 Reduce-1.91%$68.45 - $86.8
($75.89)
$ 89.0917%Reduce -51.74%144,140
CELGRay Dalio 2014-06-30 Sold Out -0.08%$68.45 - $86.8
($75.89)
$ 89.0917%Sold Out0
CELGJohn Burbank 2014-06-30 Sold Out -0.01%$68.45 - $86.8
($75.89)
$ 89.0917%Sold Out0
CELGRay Dalio 2014-03-31 Add0.07%$69.65 - $85.97
($79.51)
$ 89.0912%Add 962.69%142,400
CELGJohn Burbank 2014-03-31 Buy 0.01%$69.65 - $85.97
($79.51)
$ 89.0912%New holding, 1670 sh.3,340
CELGJohn Keeley 2014-03-31 Sold Out $69.65 - $85.97
($79.51)
$ 89.0912%Sold Out0
CELGRonald Muhlenkamp 2013-12-31 Add0.12%$72.25 - $85.39
($79.05)
$ 89.0913%Add 2.87%294,850
CELGRay Dalio 2013-12-31 Buy 0.01%$72.25 - $85.39
($79.05)
$ 89.0913%New holding, 6700 sh.13,400
CELGMario Gabelli 2013-09-30 Add$60.13 - $77.31
($70.14)
$ 89.0927%Add 29.5%20,940
CELGJohn Keeley 2013-09-30 Buy $60.13 - $77.31
($70.14)
$ 89.0927%New holding, 1320 sh.2,640
CELGJohn Hussman 2013-09-30 Sold Out -0.31%$60.13 - $77.31
($70.14)
$ 89.0927%Sold Out0
CELGRonald Muhlenkamp 2013-06-30 Reduce-0.96%$56.1 - $65.09
($60.18)
$ 89.0948%Reduce -21.92%285,770
CELGJoel Greenblatt 2013-06-30 Sold Out -0.01%$56.1 - $65.09
($60.18)
$ 89.0948%Sold Out0
CELGJohn Hussman 2013-03-31 Reduce-0.71%$39.24 - $57.96
($50.79)
$ 89.0975%Reduce -85.25%118,000
CELGJoel Greenblatt 2013-03-31 Reduce-0.17%$39.24 - $57.96
($50.79)
$ 89.0975%Reduce -94.2%4,660
CELGRay Dalio 2013-03-31 Sold Out -0.07%$39.24 - $57.96
($50.79)
$ 89.0975%Sold Out0
CELGJoel Greenblatt 2012-12-31 Add0.16%$35.65 - $41.04
($38.7)
$ 89.09130%Add 989.15%80,314
CELGMario Gabelli 2012-12-31 Add$35.65 - $41.04
($38.7)
$ 89.09130%Add 68.37%17,510
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CELG is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
CELG George Soros 2014-06-30688,0000.090.45New Buy
CELG Joel Greenblatt 2014-06-3063,9800.010.07New Buy
CELG Mario Gabelli 2014-06-3023,12000.01+7.34%
CELG Ronald Muhlenkamp 2014-06-30144,1400.022.2-51.74%
CELG Ray Dalio 2014-06-30000Sold Out
CELG John Burbank 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


CELG: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
KAPLAN GILLADirector 2014-09-08Sell30,000$93.73-2.39view
LOUGHLIN JAMES JDirector 2014-08-22Sell20,000$91.250.26view
CASEY MICHAEL DDirector 2014-08-14Sell30,000$88.593.27view
KARSEN PERRY Asee remarks 2014-08-04Sell39,104$87.554.5view
BARKER RICHARD WDirector 2014-07-25Sell17,600$87.035.12view
Celgene International Inc10% Owner 2014-07-08Buy200,000$10814.9view
KAPLAN GILLADirector 2014-06-09Sell30,000$80.8113.22view
CELGENE CORP /DE/10% Owner 2014-05-05Buy1,100,000$42.86113.46view
KARSEN PERRY Asee remarks 2014-05-01Sell23,844$73.3924.66view
Celgene European Investment Co10% Owner 2014-04-29Buy294,800$44107.93view

Press Releases about CELG :

    Quarterly/Annual Reports about CELG:

    News about CELG:

    Articles On GuruFocus.com
    Ken Fisher's Top Increases of the First Quarter Apr 22 2014 
    David Winters' 2013 Letter to Wintergreen Fund Shareholders Mar 05 2014 
    You Can No Longer Ignore Biotech Feb 07 2014 
    Trying to Beat the Market Is a Fool’s Errand Oct 17 2013 
    Insiders Are Buying Idera Pharmaceuticals Sep 19 2013 
    comment on CELG Mar 20 2013 
    Growth Stocks: There Is a Lot of Value in this Market Part 2 Sep 27 2012 
    High frowth cheap in Jun 30 2012 
    52-Week High Companies: CVS, TSM, PM, ROST, CELG Feb 27 2012 
    52-Week High Companies: CELG, MON, ECL, SBUX, NWSA Jan 16 2012 


    More From Other Websites
    Today's Thorns, Roses and All Time Highs in the Market... Sep 11 2014
    Stocks Bounce As Nasdaq, S&P 500 Close With Small Gains Sep 11 2014
    Stocks Show Modest Losses; Biotechs Pressured Again Sep 11 2014
    Short Sellers Remain Vigilant Against Biotechs Sep 11 2014
    Celgene Corporation Easing Back After Run To New All-Time Highs - Is It Buyable Yet? Sep 11 2014
    Stock Trading Ideas for 9/10/12 Sep 10 2014
    SunTrust Robinson Humphrey Starts Coverage on 5 Top Biotech Stocks Sep 08 2014
    Celgene's Revlimid Impresses in Phase III NDMM Study Sep 05 2014
    [video] 3 Biotech picks: Gilead, Biogen & Celgene Sep 05 2014
    Celgene: Good Data But What About the Patent Challenges? Sep 04 2014
    Phase III FIRST™ (MM-020/IFM 07-01) Trial of REVLIMID® (lenalidomide) Plus Dexamethasone in Newly... Sep 04 2014
    Three Stocks Top-Performing Funds Like: Facebook Baidu Gilead Sep 03 2014
    Cramer: Twitter and other 'irresistible' stocks Sep 02 2014
    Today's Thorns, Roses and All Time Highs in the Markets... Sep 02 2014
    VentiRx Pharmaceuticals Provides Corporate and Clinical Update Sep 02 2014
    Healthy Earnings Growth Sustains Pricey Biotech ETFs Aug 27 2014
    [video] Best performing September stocks Aug 27 2014
    Celgene rose 2.4% Aug 26 2014
    [video] Cramer's Mad Dash: DSW underrated Aug 26 2014
    Stocks Rise As Biotechs Lead; Amazon To Buy Twitch Aug 25 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK